As shown in Table 1, patients with imaging-defined MAFLD had significantly higher levels at admission of serum IL-6 (median 7.1 [IQR, 4.3–20.0] vs. 4.8 [2.6–11.6] pg/mL, p = 0.030; Figure 2), liver enzymes and a higher proportion of overweight/obesity and dyslipidemia compared to those without MAFLD. The gene discussed is IL6; the disease is metabolic syndrome.